Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
Vaxcyte (Nasdaq: PCVX), a clinical-stage vaccine innovation company, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's management will engage in a fireside chat on Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT.
Interested parties can access a live webcast of the discussion through the Investors & Media section of Vaxcyte's website at http://investors.vaxcyte.com. For those unable to attend the live event, a replay of the webcast will be available for approximately 30 days following the conference.
This presentation offers an opportunity for investors and analysts to gain insights into Vaxcyte's progress in developing high-fidelity vaccines aimed at protecting against bacterial diseases.
Vaxcyte (Nasdaq: PCVX), una compagnia innovativa nel campo dei vaccini in fase clinica, ha annunciato la sua partecipazione alla 2024 Cantor Global Healthcare Conference. Il management dell'azienda parteciperà a un fireside chat mercoledì 18 settembre alle 10:20 a.m. ET / 7:20 a.m. PT.
Le parti interessate possono accedere a un webcast dal vivo della discussione attraverso la sezione Investitori e Media del sito di Vaxcyte all'indirizzo http://investors.vaxcyte.com. Per coloro che non possono assistere all'evento dal vivo, sarà disponibile una registrazione del webcast per circa 30 giorni dopo la conferenza.
Questa presentazione offre un'opportunità per investitori e analisti di ottenere informazioni sui progressi di Vaxcyte nello sviluppo di vaccini ad alta fedeltà destinati a proteggere contro malattie batteriche.
Vaxcyte (Nasdaq: PCVX), una empresa innovadora en vacunas en etapa clínica, ha anunciado su participación en la 2024 Cantor Global Healthcare Conference. La dirección de la empresa participará en una charla al calor de la chimenea el miércoles 18 de septiembre a las 10:20 a.m. ET / 7:20 a.m. PT.
Las partes interesadas pueden acceder a un webcast en vivo de la discusión a través de la sección de Inversores y Medios del sitio web de Vaxcyte en http://investors.vaxcyte.com. Para quienes no puedan asistir al evento en vivo, habrá una repetición del webcast disponible durante aproximadamente 30 días después de la conferencia.
Esta presentación ofrece una oportunidad para que los inversores y analistas obtengan información sobre el progreso de Vaxcyte en el desarrollo de vacunas de alta fidelidad destinadas a proteger contra enfermedades bacterianas.
Vaxcyte (Nasdaq: PCVX), 임상 단계의 백신 혁신 회사가 2024 Cantor Global Healthcare Conference에 참여한다고 발표했습니다. 회사 경영진은 2023년 9월 18일 수요일 오전 10:20 ET / 오전 7:20 PT에 화재 옆 대화에 참여할 예정입니다.
관심 있는 분들은 Vaxcyte 웹사이트의 투자자 및 미디어 섹션을 통해 논의의 실시간 웹캐스트에 접속할 수 있습니다: http://investors.vaxcyte.com. 생중계를 관람할 수 없는 분들을 위해 회의 종료 후 약 30일 동안 웹캐스트 재생이 제공됩니다.
이번 발표는 투자자와 분석가가 Vaxcyte가 세균 질병에 대한 예방을 목표로 하는 고충실도 백신 개발에서 얻는 진전을 이해할 수 있는 기회를 제공합니다.
Vaxcyte (Nasdaq: PCVX), une entreprise innovante dans le domaine des vaccins en phase clinique, a annoncé sa participation à la 2024 Cantor Global Healthcare Conference. La direction de l'entreprise participera à une discussion informelle le mercredi 18 septembre à 10h20 ET / 7h20 PT.
Les parties intéressées peuvent accéder à un webcast en direct de la discussion via la section Investisseurs et Médias du site web de Vaxcyte à l'adresse http://investors.vaxcyte.com. Pour ceux qui ne peuvent pas assister à l'événement en direct, une rediffusion du webcast sera disponible pendant environ 30 jours après la conférence.
Cette présentation offre une opportunité aux investisseurs et aux analystes d'obtenir des insights sur les progrès de Vaxcyte dans le développement de vaccins de haute fidélité visant à protéger contre les maladies bactériennes.
Vaxcyte (Nasdaq: PCVX), ein innovatives Unternehmen im Bereich klinischer Impfstoffe, hat seine Teilnahme an der 2024 Cantor Global Healthcare Conference bekannt gegeben. Das Management des Unternehmens wird an einem Fireside Chat am Mittwoch, den 18. September, um 10:20 Uhr ET / 7:20 Uhr PT teilnehmen.
Interessierte können über den Bereich Investoren & Medien auf der Website von Vaxcyte auf ein Live-Webcast der Diskussion zugreifen unter http://investors.vaxcyte.com. Für diejenigen, die nicht an der Live-Veranstaltung teilnehmen können, wird eine Wiederholung des Webcasts für ca. 30 Tage nach der Konferenz verfügbar sein.
Diese Präsentation bietet Investoren und Analysten die Möglichkeit, Einblicke in die Fortschritte von Vaxcyte bei der Entwicklung hochtreuer Impfstoffe zu erhalten, die auf den Schutz gegen bakterielle Krankheiten abzielen.
- None.
- None.
SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT.
A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.
About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. VAX-31 is a Phase 3-ready 31-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is currently being evaluated in a Phase 2 infant study. Both VAX-31 and VAX-24 are designed to improve upon the standard-of-care PCVs by covering the serotypes in circulation that are responsible for a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice.
Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.
For more information, visit www.vaxcyte.com.
Contacts:
Jennifer Zibuda, Senior Director, Investor Relations
Vaxcyte, Inc.
860-729-8902
investors@vaxcyte.com
Patrick Ryan, Executive Director, Corporate Communications
Vaxcyte, Inc.
(415) 606-5135
media@vaxcyte.com
FAQ
When is Vaxcyte (PCVX) presenting at the 2024 Cantor Global Healthcare Conference?
How can I watch Vaxcyte's (PCVX) presentation at the 2024 Cantor Global Healthcare Conference?
How long will the replay of Vaxcyte's (PCVX) 2024 Cantor Global Healthcare Conference presentation be available?
What type of company is Vaxcyte (PCVX)?
